Q-omics provides the consensus-scored CDRT15P7 profile across patient tissues and cancer cell-line models. CDRT15P7 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CDRT15P7 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, CDRT15P7 RNA expression shows 6,021 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUAD, and STAD as cancer lineages where CDRT15P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15P7 survival associations across molecular data types. CDRT15P7 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15P7 RNA expression–survival associations across cancer types. High CDRT15P7 expression shows unfavorable associations in THCA, PAAD, THYM, BLCA and LAML, but favorable associations in LUSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CDRT15P7 RNA expression.
This table summarizes CDRT15P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15P7 shows lower tumor expression in KIRP and THCA and higher tumor expression in LUAD. The LUAD box plot shows higher CDRT15P7 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .008).
This table shows molecular features associated with CDRT15P7 in patient tissues and cancer cell lines. In patient samples, CDRT15P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
